Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma.
Three inhalation formulations of ICI 204,219 were compared for antagonism of antigen-induced bronchoconstriction in 16 subjects with asthma who demonstrated reproducible hypersensitivity to allergen during screening challenges. Each subject received a single 0.2-mg dose of each formulation and was challenged with ragweed 30 min after administration of ICI 204,219 until the forced expiratory volume in 1 s (FEV1) decreased by 20 percent or the maximum allergen concentration (100 micrograms/ml) was reached. The majority of subjects tolerated 100 micrograms/ml of allergen without a 20 percent decrease in FEV1. Inhalation formulations of ICI 204,219 successfully inhibited bronchoconstriction in subjects with reproducible sensitivity to ragweed challenges.
Nathan
R A
RA
Allergy Associates, Colorado Springs, Colo.
Glass
M
M
Minkwitz
M C
MC
D000280:Administration, Inhalation; D000328:Adult; D000485:Allergens; D000941:Antigens; D001249:Asthma / Q000517:prevention & control*; D001985:Bronchial Provocation Tests; D016084:Bronchoconstriction / Q000187:drug effects*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007211:Indoles; D017998:Leukotriene D4 / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D048448:Phenylcarbamates; D011058:Pollen; D015203:Reproducibility of Results; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D014797:Vital Capacity / Q000187:drug effects
D000485:Allergens; D000941:Antigens; D007211:Indoles; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; D017998:Leukotriene D4; C062735:zafirlukast